Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 5/2005

01-09-2005 | Commentary

DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis

Authors: Piet LCM van Riel, Jaap Fransen

Published in: Arthritis Research & Therapy | Issue 5/2005

Login to get access

Abstract

The Disease Activity Score using 28 joint counts (DAS28) has been developed in a cohort of patients with rheumatoid arthritis in which only conventional anti-rheumatic treatments were used. It has extensively been validated to monitor disease activity in daily clinical practice as well as in clinical trials. The study of Vander Cruyssen and colleagues showed that the DAS28 correlated best with the decisions of rheumatologists to increase the infliximab dose because of insufficient response. This result once more confirms the validity of the DAS28 to monitor disease activity in patients with rheumatoid arthritis and to titrate treatment with biologicals.
Literature
1.
Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Veys EM, Mielants H, De Clerck L, Peretz A, et al: DAS28 reflects best the physician's clinical judgement of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther. 2005, 7: R1063-R1071. 10.1186/ar1787.PubMedCentralCrossRefPubMed
2.
Durez P, Van den Bosch F, Corluy L, Veijs EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, et al: A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology. 2005, 44: 465-468. 10.1093/rheumatology/keh494.CrossRefPubMed
3.
Heijde van der DMFM, Hof van't MA, Riel van PLCM, Theunisse HAM, Lubberts EW, Leeuwen van MA, Rijswijk van MH, Putte van de LBA: Judging disease activity in clinical practice in rheumatoid arthritis. First step in the development of a 'disease activity score'. Ann Rheum Dis. 1990, 49: 916-920.CrossRef
4.
Prevoo MLL, Hof van't MA, Kuper HH, Leeuwen van MA, Putte van de LBA, Riel van PLCM: Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38: 44-48.CrossRefPubMed
5.
Fransen J, Stucki G, Riel van PLCM: Rheumatoid arthritis measures. Arthritis Rheum (Arthritis Care Res). 2003, 49: 214-224. 10.1002/art.11407.CrossRef
6.
Salafi F, Peroni M, Ferraccioli GF: Discriminative ability of composite indices for measuring disease activity in rheumatoid arthritis: a comparison of the Chronic Arthritis Systemic index, Disease Activity Score and Thompson's Articular Index. Rheumatology. 2000, 39: 90-96. 10.1093/rheumatology/39.1.90.CrossRef
7.
Aletaha D, Ward M, Machold K, Nell VPK, Stamm T, Smolen JS: Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states [abstract 0346]. Ann Rheum Dis. 2005, 64 (Suppl III): 214-
8.
Broeder den AA, Creemers MCW, Gestel van AM, Riel van PLCM: Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti TNF-α. Rheumatology. 2002, 41: 638-642. 10.1093/rheumatology/41.6.638.CrossRef
Metadata
Title
DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis
Authors
Piet LCM van Riel
Jaap Fransen
Publication date
01-09-2005
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2005
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1820

Other articles of this Issue 5/2005

Arthritis Research & Therapy 5/2005 Go to the issue

Research article

Sex hormone modulation of cell growth and apoptosis of the human monocytic/macrophage cell line

Research article

Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis

Commentary

Opioids for non-operable osteoarthritis and soft-tissue rheumatism

Research article

Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis

Research article

Altered dendritic cell distribution in patients with common variable immunodeficiency

Research article

Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits